Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezefeno in Dyslipidemia Patients with Type 2 Diabetes
NCT06293417Recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Mar 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe + fenofibrate in dyslipidemia (2 arms), sponsored by Korea University Anam Hospital. Primary endpoints: Major Adverse Cardiovascular Events at 48 months and Diabetic Microvascular Events at 48 months. Started Mar 2024; status: recruiting.
02
Drugs
ezetimibe + fenofibrate
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06293417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293417.